These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 9061694

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer.
    Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, Palmedo H, Ruhlmann J, Kozak B, Biersack HJ.
    Eur J Nucl Med; 1996 Mar; 23(3):312-9. PubMed ID: 8599963
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P, Gallowitsch HJ.
    Acta Med Austriaca; 1996 Mar; 23(1-2):69-75. PubMed ID: 8767519
    [Abstract] [Full Text] [Related]

  • 27. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose.
    Joensuu H, Ahonen A.
    J Nucl Med; 1987 May; 28(5):910-4. PubMed ID: 3572549
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
    Hsu CH, Liu FY, Yen RF, Kao CH.
    Endocr Res; 2003 Feb; 29(1):9-15. PubMed ID: 12665314
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P.
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The role of 99Tcm-sestamibi scintigraphy in the staging and prediction of the therapeutic response of stage IV neuroblastoma: comparison with 131I-MIBG and 99Tcm-MDP scintigraphy.
    Burak Z, Yüksel DA, Cetingül N, Kantar M, Ozkiliç H, Moretti JL.
    Nucl Med Commun; 1999 Nov; 20(11):991-1000. PubMed ID: 10572908
    [Abstract] [Full Text] [Related]

  • 36. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B, Nopmaneejumruslers C, Pusuwan P, Tuchinda P, Tojinda N, Ubolnuch K.
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [Abstract] [Full Text] [Related]

  • 37. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, López de la Torre M, Becerra A, Carreras JL.
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [Abstract] [Full Text] [Related]

  • 38. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome).
    Ranade R, Kand P, Basu S.
    Nucl Med Commun; 2015 Oct; 36(10):1014-20. PubMed ID: 26049373
    [Abstract] [Full Text] [Related]

  • 39. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
    Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N.
    J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
    [Abstract] [Full Text] [Related]

  • 40. The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 131I whole body scan: a single-center study of 108 patients.
    Choi MY, Chung JK, Lee HY, So Y, Park DJ, Jeong JM, Lee DS, Lee MC, Cho BY.
    Ann Nucl Med; 2006 Oct; 20(8):547-52. PubMed ID: 17134022
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.